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Strengths and limitations of this study
 ► The application of a retrospective study covering 18 
years allows obtaining a clear view of disease status 
in the country.
 ► The inclusion of inpatient and outpatient care data 
provides a consistent basis for the analysis of medi-
cal costs in specialised care settings.
 ► A higher specificity of the International Classification 
of Diseases, Ninth revision, Clinical Modification 
(ICD9- CM) codes would permit an improved analysis.
 ► The calculation of direct medical costs excludes 
pharmaceutical expenses, unknown due to their ex-
clusion from patient records.
AbStrACt
Objectives To analyse the characteristics of patients 
diagnosed with spinal muscular atrophy in Spain, and to 
revise data on disease management and use of resources 
in both public and private healthcare centres.
Design A retrospective multicentre database analysis.
Setting 870 admission records registered between 1997 
and 2015 with a diagnosis of spinal muscular atrophy 
were extracted from a Spanish claims database that 
includes hospital inpatient and outpatient admissions from 
313 public and 192 private hospitals in Spain.
results Admission files corresponded to 705 patients; 
61.99% were males and 38.01% females. Average patient 
age was 37 years. Disease comorbidities registered during 
the admission consistently included hypertension, scoliosis 
and respiratory failures, all associated with the standard 
disease course. Regarding disease management at the 
hospital level, patients were mostly admitted through 
scheduled appointments (58.16%), followed by emergency 
admissions (41.72%), and into neurology services in 17% 
of the cases. Mean hospitalisation time was 10.45 days 
and in- hospital mortality reached 5.29%. The overall 
direct medical costs of spinal muscular atrophy were 
€291 525, excluding medication. The average annual cost 
per admission was €6274, with large variations likely to 
reflect disease complexity and that increases with length 
of stay.
Conclusions The rarity of the disease difficulties the 
study of demographics and management; yet, an analysis 
of patient characteristics provides necessary information 
that can be used by governments to establish more 
efficient healthcare protocols. This study reflects the 
impact that individual needs and disease severity can have 
in disease burden calculations. Forthcoming decision- 
making policies should take into account medical costs 
and its variability, as well as pharmaceutical expenses 
and indirect costs. To our knowledge, this is the first study 
evaluating the use of healthcare resources of patients with 
spinal muscular atrophy in Spain.
IntrODuCtIOn
Spinal muscular atrophy (SMA) is a rare, 
hereditary and recessive neuromuscular 
disorder caused by the degeneration of the 
alpha motor neurons of the spinal cord.1 
The term SMA makes reference to a group 
of genetic disorders characterised by mild to 
severe muscle atrophy and weakness.
SMA has generally been divided into four 
to five types based on patients’ motor func-
tion and disease age of onset. Type I, also 
called Werdnig- Hoffmann syndrome, is diag-
nosed at birth or in the first 6 months of life, 
and causes severe development limitations 
that generally lead to patients’ death before 
2 years of age. Type II has its onset between 
7 and 18 months of age, before the child is 
able to walk. Type III (Kugelberg- Welander 
syndrome) can be divided in two subtypes; 
type IIIa is diagnosed in children of 2–3 years 
of age, who will have orthopaedic issues; and 
type IIIb has its onset between 3 years of age 
and late adolescence, and patients generally 
have a normal motor development.2 3
A fourth type of SMA has been later 
described to refer to SMA with an adult onset, 
in people that are able to walk. Type 0 has 
been used to refer to the disease in children 
in the first weeks of their life.2 4
Recent research has allowed identifying 
and describing most genetic variants associ-
ated with SMA, all mutations in the survival 
of motor neurons (SMN1) gene, but disease 
pathogenesis is still not fully understood. 
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Figure 1 Distribution of male and female patients per year.
Data on disease occurrence and epidemiology are also 
scarce for some regions of the planet. Also, the relative 
rarity of the disease can lead to major miscalculations in 
disease prevalence and incidence rates.5
SMA has been estimated to affect 1 in 6000–10 000 chil-
dren.6 In addition, 1 in 40 individuals are estimated to be 
carriers of the recessive mutation.
Several studies in countries like Iceland, Sweden, the 
UK, Germany, Italy and Canada show an irregular distri-
bution of SMA patients around the world depending 
on the region and population characteristics.7 SMA 
incidence in these countries ranged from 6 per 100 000 
people in Canada to 13.7 per 100 000 people in Iceland.
In terms of costs, the economic impact of attending 
SMA patients and their care has only been partially 
evaluated. A previous study in Spain based on question-
naires filled by caregivers showed the high costs that 
these assume in terms of healthcare and indirect costs 
associated with the disease, and a posterior similar study 
in Australia confirmed that the burden for families is 
extremely high8 9; nevertheless, the costs it has for health-
care systems have not been evaluated in the country.
Thus, the objective of this study was to analyse SMA 
patient characteristics and number of diagnoses between 
1997 and 2015 in Spain, and to revise data on disease 
management and these patients’ use of resources in both 
public and private healthcare centres.
MethODS
A retrospective study was conducted based on data from 
the Spanish claims database Minimum Basic Data Set 
(Conjunto Mínimo Básico de Datos (CMBD)),10 a data-
base administered by the Spanish Ministry of Health that 
compiles records from 313 public and 192 private hospi-
tals representative of the Spanish population.
All admission files registered between 1997 and 2015 
in which SMA was listed as the principal diagnosis 
(admission motive) were identified and extracted via the 
International Classification of Diseases, Ninth revision, 
Clinical Modification (ICD9- CM) codes 335.0, 335.10, 
335.11, 335.19 and 335.21 corresponding to patients with 
Werdnig- Hoffmann, Kugelberg- Welander, any progres-
sive SMA, unspecified SMA and other SMA types.
Each admission file contained patient general infor-
mation (sex, age and region of residence), admission 
details (type of admission, length of stay and destination 
after discharge), secondary diagnoses and procedures 
performed during the admission (codified using ICD9- CM 
and ICD9, Procedure Classification System (ICD9- PCS) 
codes) and the hospitalisation cost that included treat-
ment (examination, medication and surgery) and costs 
associated to medical staff, equipment and resources. 
Such cost was given as a total value based on the tariffs of 
medical procedures determined by the Spanish Ministry 
of Health for the year when the admission took place. 
The years 1997 and 1998 were excluded from the analysis 
of secondary care costs to ensure data consistency after 
the detection of codification errors.
The complete admission data were used to analyse 
disease management. For the analysis of patient demo-
graphics and comorbidities, only the first admission 
per patient during the study period (1997–2015) was 
considered.
Records were extracted after the re- coding of health 
centres and medical history identifiers to maintain 
anonymity in accordance with the principles of Good 
Clinical Practice and the Declaration of Helsinki.
Data presentation is mainly descriptive. All statistical 
analyses were performed using Microsoft Excel Profes-
sional Plus 2010 (Microsoft Corporation, Redmond, WA, 
USA).
Patient and public involvement
Patients were not directly involved in the research or the 
study design. Results will not be disseminated to patients 
included in the database.
reSultS
Patient characteristics
Altogether, 870 inpatient and outpatient admissions were 
identified in the CMBD database, which corresponded to 
single and repeated admissions of 705 patients with SMA.
The 61.99% of the 705 patients included in the study 
were males, while 38.01% were females, with relatively 
large variations in these proportions over the years 
(figure 1).
When considering solely data recovered from the first 
admission per patient during the study period, mean 
patient age was 37 years, with virtually no differences 
among sexes. To minimise errors, any changes in patients’ 
mean age at first admission over the study period were 
measured. Nonetheless, patients’ average age did not 
exhibit large variations over the years, with a SD of only 
5.87 years (data not shown).
Each file included data of secondary diagnoses regis-
tered during the admission, used to analyse comorbid-
ities. The most repeated comorbidities in patients with 
SMA were: hypertension (14.89%), scoliosis (10.21%), 
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Table 1 Comorbidities in SMA patients
Disease description (ICD9- CM 
code)
Number of 
patients
% of 
patients
Unspecified essential 
hypertension (401.9)
105 14.89
Scoliosis associated with other 
conditions (737.43)
72 10.21
Chronic respiratory failure (518.83) 45 6.38
Diabetes mellitus type I- II (250) 42 5.96
Tobacco use disorders (305.1) 42 5.96
Acute respiratory failure (518.81) 37 5.25
ICD9- CM, International Classification of Diseases, Ninth revision, 
Clinical Modification; SMA, spinal muscular atrophy.
Table 2 Type of admissions, readmissions and discharge 
of SMA patients
Origin of admission
Number of 
admissions
% of 
admissions
  Scheduled 506 58.16
  Emergency 363 41.72
  Others 1 0.12
Destination after discharge
  Home 796 91.50
  Death 46 5.29
  Other hospitals 17 1.95
  Voluntary 3 0.34
  Transfer to a social health 
centre
2 0.23
  Others 6 0.69
Readmissions 99 11.38
SMA, spinal muscular atrophy.
Table 3 Services that attended SMA patients and 
procedures performed on admission
Number of 
patients
% of 
patients
Service
  Neurology 154 17.70
  Paediatrics 79 9.08
  Traumatology and 
orthopaedics
54 6.21
  Pneumology 47 5.40
  Internal medicine 33 3.79
Procedure (ICD9- PCS code)
  Electromyography (93.08) 182 20.92
  MRI scan of the brain and 
brainstem (88.91)
104 11.95
  MRI scan of the spinal canal 
(88.93)
103 11.84
  Lumbar puncture (03.31) 99 11.38
  Routine chest radiography 
(87.44)
74 8.51
  Microscopic examination of 
the blood (90.59)
74 8.51
  Non- invasive mechanical 
ventilation (93.90)
71 8.16
  Electrocardiogram (89.52) 67 7.70
  Arterial blood gas test (89.65) 57 6.55
  Other oxygenation 
procedures (93.96)
52 5.98
ICD9- PCS, International Classification of Diseases, Ninth Revision, 
Procedure Classification System; SMA, spinal muscular atrophy.
chronic respiratory failure (6.38%), diabetes mellitus 
(5.96%), tobacco use disorders (5.96%) and acute respi-
ratory failure (5.25%) (table 1).
use of healthcare resources
Regarding hospitalisation events, scheduled admissions 
were predominant (58.16%), followed by emergency 
admissions (41.72%) (table 2).
The average hospitalisation time was 10.45 days. Patients 
were discharged mostly to their residence (91.50%), 
although 5.29% died during the hospitalisation event. In 
addition, 11.38% of the patients were readmitted within 
the following 30 days after discharge.
Neurology admitted 17.70% of the patients, paediat-
rics 9.08%, traumatology 6.21%, pneumology 5.40%, 
internal medicine 3.79% and the rest of admissions were 
into other services or unregistered (table 3). The most 
repeated procedures performed during the admission 
were also analysed. Common procedures were related to 
neuromuscular tests, medical imaging and ventilation or 
oxygenation (table 3).
As for medical costs related to the use of resources, the 
average annual cost of the disease at the hospital level was 
€291 525, excluding pharmaceutical expenses. The cost per 
hospitalisation was on average €6274, ranging from €2569 
to €112 067 (table 4). The cost per admission appeared 
increased in the year 2012 due to the high costs registered 
in one admission of a patient with Kugelberg- Welander 
(reaching €112 067); this could reflect the impact in terms 
of cost that is derived from the most severe cases. The anal-
ysis of admission costs per SMA type showed major expenses 
related to Kugelberg- Welander, averaging €9415, and mean 
costs per admission of €5770, €5751, €5286 and €5379 in 
patients with Werdnig- Hoffmann, progressive SMA, other 
SMA types and unspecified SMA, respectively.
Finally, the impact of the length of stay in hospitalisa-
tion costs was evaluated. Outpatient admissions displayed 
a mean cost of €5603 per visit, while inpatient care admis-
sions displayed increasing costs that augmented alongside 
the length of stay (table 5). Yet, wide variability appeared 
linked to individual patient needs.
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Table 4 Mean and range of costs per hospital admission 
per year (1999–2015)
Year Mean (SD) Range Admissions
1999 €4196 (€1437) €2709–€9566 39
2000 €4051 (€809) €2709–€7072 33
2001 €5724 (€7292) €3023–€40 619 25
2002 €5437 (€6116) €3003–€41 395 39
2003 €4672 (€1275) €3305–€9282 36
2004 €7153 (€11 308) €3400–€47 560 29
2005 €4584 (€2132) €2569–€12 589 37
2006 €4876 (€3402) €2876–€15 622 50
2007 €7243 (€7908) €2997–€55 979 55
2008 €8048 (€7542) €3303–€47 907 47
2009 €5223 (€3323) €3329–€15 182 46
2010 €5493 (€3530) €3541–€21 308 57
2011 €8981 (€14 145) €3626–€81 742 39
2012 €10 088 (€18 472) €3502–€112 067 53
2013 €6890 (€9266) €4129–€69 361 51
2014 €6644 (€4764) €3454–€24 947 53
2015 €7358 (€8098) €3759–€52 764 81
Table 5 Mean cost per admission per length of stay
Days Mean Range
Outpatient care €5603 €3400–€8014
Inpatient care
  1–10 €5276 €2569–€81 742
  11–30 €7858 €2876–€52 764
  31–60 €12 369 €2997–€69 361
  >60 €32 692 €4061–€112 067
The vast majority of patients were financed by the 
Spanish social security system (94.61%), 1.84% were 
financed by local corporations, 1.28% by mutual health-
care and the rest were private or unknown.
DISCuSSIOn
Patient characteristics
The understanding of SMA molecular basis has increased 
dramatically in the past years; however, patient character-
istics, disease occurrence and managing have not been 
analysed in many countries. Regional disease demo-
graphics provide interesting information that can be 
used by regional governments to establish more efficient 
healthcare protocols and to develop research that satisfies 
the population needs. In addition, an irregular geograph-
ical distribution of SMA has been previously observed 
depending on the region and population characteristics,7 
thus the interest of understanding any variations that may 
occur in Spain.
This study sheds light into the current status of SMA 
in the country via the analysis of medical records from 
1997 to 2015. The inclusion of 18 years of records allows 
a more consistent analysis of a condition with, otherwise, 
few diagnosed cases. Overall, 705 patients were iden-
tified with a diagnosis of SMA in the database, with a 
proportion 60 to 40 male/female, which is seemingly not 
explained by the described genetic basis of SMA. Previous 
studies including data from the USA found proportions 
of female patients of 54.8% and 56.9% for total SMA and 
SMA- I, respectively.11 12 However, ICD-9 codes used to 
identify SMA include variations of the disease as progres-
sive muscular atrophy (Aran- Duchenne disease), known 
to be more common in males than in females with a ratio 
of 3:1.13 Patients’ age, on the other hand, is equal in both 
sexes and relatively high (37 years), although this age 
registered at first admission cannot be translated to age of 
diagnosis given the inclusion in the study of patients diag-
nosed before 1997. In general terms, age of first diagnosis 
has been estimated around 7.5±6.4 years12; yet, it is highly 
variable among the distinct SMA types.4 In addition, when 
diagnosis is based on pre- natal screening, it is considered 
pre- symptomatic and registered earlier in life.14
Nevertheless, the importance of the typical clinical 
manifestations of SMA is clear, and its disease comorbid-
ities have been vastly described, including conditions as 
scoliosis and respiratory failures, commonly diagnosed in 
this study among SMA patients.15 In fact, previous data 
suggest that scoliosis is present in virtually all type II and 
type IIIa SMA patients, and it appears progressively in 
patients with type IIIb SMA.3 16 Scoliosis can have severe 
effects in patients’ respiratory capacities, with conse-
quences that justify the prevalence of respiratory failure 
among these patients.3 This validates the importance to 
tackle orthopaedic manifestations of SMA in early phases 
of the disease. On the other hand, the high presence of 
hypertension among these patients must be evaluated 
considering the significantly high presence of hyperten-
sive adults in the country, which was 42.6% in 2016.17
use of healthcare resources
The analysis of this admission- based database provides 
data on patients’ use of resources and an approxima-
tion to current disease management at the hospital level. 
Overall, patients’ hospitalisation data show a high preva-
lence of scheduled admissions, although the importance 
of emergency consultations is not minor as they reach 
41.72% of total files. Most patients were admitted into 
neurology services, followed by paediatrics. Research 
arguments the need to establish a multidisciplinary 
approach to the disease, where all physicians involved are 
coordinated and aware of the disease course which could 
facilitate patient treatment and improve patients’ prog-
nosis18; this would be especially relevant for the care of 
paediatric patients.
The average hospitalisation time, of ten days, is similar 
to findings in previous studies and has been mostly asso-
ciated with managing respiratory complications,19 as 
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many patients require persistent mechanical ventilation. 
This implicates that enormous changes in costs may 
appear derived from differences in disease severity, since 
prolonged hospitalisations account for larger medical 
costs. This can be observed in the disaggregated anal-
ysis of annual costs, where individual expenses reached 
figures distant from the total average. Thus, variations 
on admission costs over the years are not explained by 
an increase in patient or hospitalisation number and are 
extremely dependent on small oscillations in diagnosis- 
related groups that determine procedures costs and on 
individual patients requiring more specialised proce-
dures, probably due to an increased degree of severity of 
the disease.
The annual cost of SMA at the hospital level in Spain, 
of €291 525, is not comparable to medical costs of 
€600 million that were estimated in the whole USA in 
2010. However, it is a figure likely to increase once pharma-
ceutical expenses and other medical costs are considered. 
The annual cost per admission, of €6274, is not distant 
to that in children with SMA in the USA, where it ranged 
from around €5200 to €44 400, increasing with the pres-
ence of other complex chronic conditions.11 At a smaller 
scale, another study based on the US military healthcare 
system data estimated a cost of €42 300 per year,13 while 
in Germany the mean annual cost per patient was around 
€70 600.20 These figures were obtained considering a 
wider range of factors such as pharmaceutical treatment, 
travel expenses, informal care and other indirect costs 
that must be considered in Spain for upcoming resource 
allocation decisions.
The quantification of the cost that SMA represents for 
the healthcare system in terms of use of resources is vital 
for resource allocation and decision- making. Evidence- 
informed decision- making based on real- world data such 
as that extracted from the CMBD database has been vital 
to improve healthcare systems, as it has been outlined 
by the WHO.21 Disease burden evaluations have been 
used with this aim in multiple occasions in regions with 
distinct healthcare system frameworks.22–24 Herein, the 
impact of this study is limited by several factors including 
the lack of pharmaceutical data and the low specificity of 
ICD9- CM codes that impede an analysis per SMA type. 
Further research will be required in the country using the 
mentioned variables.
COnCluSIOnS
The rarity of SMA has limited the number of studies 
analysing the portion of population that is affected and 
how the disease is managed, including the medical costs 
associated with it. The analysis of 18 years of medical 
records allows a clearer analysis of patient character-
istics and disease burden. Medical costs increase with 
length of stay and vary greatly with individual patient 
characteristics. This study highlights the importance of 
understanding patient characteristics and physicians’ 
management of the disease to establish more efficient 
protocols, including a multidisciplinary approach that 
involves neurologists, paediatric neurologists, orthopae-
dics and all physicians responsible for these patients.
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